A Randomized, Dose-ranging, Open-label, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of Palonosetron HCl Buccal Film Versus IV Palonosetron 0.25 mg for the Prevention of CINV in Cancer Patients Receiving MEC
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Palonosetron (Primary) ; Dexamethasone; Palonosetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Sponsors LP Pharmaceuticals
Most Recent Events
- 13 May 2021 Status changed from recruiting to completed.
- 27 Jan 2021 Planned End Date changed from 31 Dec 2020 to 30 Apr 2021.
- 27 Jan 2021 Planned primary completion date changed from 31 Dec 2020 to 28 Feb 2021.